{"protocolSection":{"identificationModule":{"nctId":"NCT04881760","orgStudyIdInfo":{"id":"18122"},"secondaryIdInfos":[{"id":"J1I-MC-GZBF","type":"OTHER","domain":"Eli Lilly and Company"}],"organization":{"fullName":"Eli Lilly and Company","class":"INDUSTRY"},"briefTitle":"A Study of LY3437943 in Participants Who Have Obesity or Are Overweight","officialTitle":"A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities"},"statusModule":{"statusVerifiedDate":"2023-08","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2021-05-20","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2022-05-16","type":"ACTUAL"},"completionDateStruct":{"date":"2022-11-22","type":"ACTUAL"},"studyFirstSubmitDate":"2021-05-10","studyFirstSubmitQcDate":"2021-05-10","studyFirstPostDateStruct":{"date":"2021-05-11","type":"ACTUAL"},"resultsFirstSubmitDate":"2023-08-23","resultsFirstSubmitQcDate":"2023-08-23","resultsFirstPostDateStruct":{"date":"2023-09-13","type":"ACTUAL"},"dispFirstSubmitDate":"2023-05-10","dispFirstPostDateStruct":{"date":"2023-05-15","type":"ACTUAL"},"lastUpdateSubmitDate":"2023-08-23","lastUpdatePostDateStruct":{"date":"2023-09-13","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Eli Lilly and Company","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This is a study of LY3437943 in participants who have obesity or are overweight. The main purpose is to learn more about how LY3437943 affects body weight loss. The study will last about 18 months and may include up to 18 visits."},"conditionsModule":{"conditions":["Obesity","Overweight"],"keywords":["Nutritional or Metabolism Disorder","Weight Loss","Overnutrition","Incretins","Hormones","Physiological Effects of Drugs"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":338,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","description":"Participants received placebo matched to LY3437943 administered as subcutaneous (SC) injection once-weekly (QW).","interventionNames":["Drug: Placebo"]},{"label":"1 milligram (mg) LY3437943","type":"EXPERIMENTAL","description":"Participants received 1 mg LY3437943 administered as SC injection QW.","interventionNames":["Drug: LY3437943"]},{"label":"4 mg LY3437943 (2 mg)","type":"EXPERIMENTAL","description":"Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 administered as SC injection QW.","interventionNames":["Drug: LY3437943"]},{"label":"4 mg LY3437943","type":"EXPERIMENTAL","description":"Participants received 4 mg LY3437943 administered as SC injection QW.","interventionNames":["Drug: LY3437943"]},{"label":"8 mg LY3437943 (2 mg)","type":"EXPERIMENTAL","description":"Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 and then 8 mg LY3437943 administered as SC injection QW.","interventionNames":["Drug: LY3437943"]},{"label":"8 mg LY3437943 (4 mg)","type":"EXPERIMENTAL","description":"Participants received 4 mg LY3437943 starting dose followed by 8 mg LY3437943 administered as SC injection QW.","interventionNames":["Drug: LY3437943"]},{"label":"12 mg LY3437943 (2 mg)","type":"EXPERIMENTAL","description":"Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943, 8 mg LY3437943 and then 12 mg LY3437943 administered as SC injection QW.","interventionNames":["Drug: LY3437943"]}],"interventions":[{"type":"DRUG","name":"LY3437943","description":"Administered SC","armGroupLabels":["1 milligram (mg) LY3437943","12 mg LY3437943 (2 mg)","4 mg LY3437943","4 mg LY3437943 (2 mg)","8 mg LY3437943 (2 mg)","8 mg LY3437943 (4 mg)"]},{"type":"DRUG","name":"Placebo","description":"Administered SC","armGroupLabels":["Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Mean Percent Change From Baseline in Body Weight","description":"Least squares (LS) means were calculated using a mixed-effects model for repeated measures (MMRM) for post-baseline measures: Variable = Treatment\\*Time + Baseline BMI (\\< 36kg/m2 vs. \\>=36 kg/m2)\\*Time + Sex (Female vs. Male)\\*Time + Baseline\\*Time.","timeFrame":"Baseline, Week 24"}],"secondaryOutcomes":[{"measure":"Mean Percent Change From Baseline in Body Weight","description":"LS means were calculated using a MMRM model for post-baseline measures: Variable = Treatment\\*Time + Baseline BMI (\\< 36kg/m2 vs. \\>=36 kg/m2)\\*Time + Sex (Female vs. Male)\\*Time + Baseline\\*Time.","timeFrame":"Baseline, Week 48"},{"measure":"Percentage of Participants Who Achieve ≥ 5% Body Weight Reduction","description":"Percentage of participants who achieve ≥ 5% body weight reduction in LY3437943 relative to placebo. Estimated percentage was determined by logistic regression model with an intercept term, treatment group, baseline BMI stratum \\[\\<36 kilograms per square meter (kg/m2), ≥36 kg/m2\\] and sex \\[female, male\\] as fixed effects, and baseline body weight as a covariate.","timeFrame":"Week 24"},{"measure":"Percentage of Participants Who Achieve ≥ 5% Body Weight Reduction","description":"Percentage of participants who achieve ≥ 5% body weight reduction in LY3437943 relative to placebo. Estimated percentage was determined by logistic regression model with an intercept term, treatment group, baseline BMI stratum \\[\\<36 kg/m2, ≥36 kg/m2\\] and sex \\[female, male\\] as fixed effects, and baseline body weight as a covariate.","timeFrame":"Week 48"},{"measure":"Percentage of Participants Who Achieve ≥ 10% Body Weight Reduction","description":"Percentage of participants who achieve ≥ 10% body weight reduction in LY3437943 relative to placebo. Estimated percentage was determined by logistic regression model with an intercept term, treatment group, baseline BMI stratum \\[\\<36 kg/m2, ≥36 kg/m2\\] and sex \\[female, male\\] as fixed effects, and baseline body weight as a covariate.","timeFrame":"Week 24"},{"measure":"Percentage of Participants Who Achieve ≥ 10% Body Weight Reduction","description":"Percentage of participants who achieve ≥ 10% body weight reduction in LY3437943 relative to placebo. Estimated percentage was determined by logistic regression model with an intercept term, treatment group, baseline BMI stratum \\[\\<36 kg/m2, ≥36 kg/m2\\] and sex \\[female, male\\] as fixed effects, and baseline body weight as a covariate.","timeFrame":"Week 48"},{"measure":"Percentage of Participants Who Achieve ≥ 15% Body Weight Reduction","description":"Percentage of participants who achieve ≥ 15% body weight reduction in LY3437943 relative to placebo. Estimated percentage was determined by logistic regression model with an intercept term, treatment group, baseline BMI stratum \\[\\<36 kg/m2, ≥36 kg/m2\\] and sex \\[female, male\\] as fixed effects, and baseline body weight as a covariate.","timeFrame":"Week 24"},{"measure":"Percentage of Participants Who Achieve ≥ 15% Body Weight Reduction","description":"Percentage of participants who achieve ≥ 15% body weight reduction in LY3437943 relative to placebo. Estimated percentage was determined by logistic regression model with an intercept term, treatment group, baseline BMI stratum \\[\\<36 kg/m2, ≥36 kg/m2\\] and sex \\[female, male\\] as fixed effects, and baseline body weight as a covariate.","timeFrame":"Week 48"},{"measure":"Mean Change From Baseline in Body Weight","description":"LS means were calculated using a MMRM model for post-baseline measures: Variable = Treatment\\*Time + Baseline BMI (\\< 36kg/m2 vs. \\>=36 kg/m2)\\*Time + Sex (Female vs. Male)\\*Time + Baseline\\*Time.","timeFrame":"Baseline, Week 24"},{"measure":"Mean Change From Baseline in Body Weight","description":"LS means were calculated using a MMRM model for post-baseline measures: Variable = Treatment\\*Time + Baseline BMI (\\< 36kg/m2 vs. \\>=36 kg/m2)\\*Time + Sex (Female vs. Male)\\*Time + Baseline\\*Time.","timeFrame":"Baseline, Week 48"},{"measure":"Mean Change From Baseline in BMI","description":"LS means were calculated using a MMRM model for post-baseline measures: Variable = Treatment\\*Time + Baseline BMI (\\< 36kg/m2 vs. \\>=36 kg/m2)\\*Time + Sex (Female vs. Male)\\*Time + Baseline\\*Time.","timeFrame":"Baseline, Week 24"},{"measure":"Mean Change From Baseline in BMI","description":"LS means were calculated using a MMRM model for post-baseline measures: Variable = Treatment\\*Time + Baseline BMI (\\< 36kg/m2 vs. \\>=36 kg/m2)\\*Time + Sex (Female vs. Male)\\*Time + Baseline\\*Time.","timeFrame":"Baseline, Week 48"},{"measure":"Mean Change From Baseline in Waist Circumference","description":"LS means were calculated using a MMRM model for post-baseline measures: Variable = Treatment\\*Time + Baseline BMI (\\< 36kg/m2 vs. \\>=36 kg/m2)\\*Time + Sex (Female vs. Male)\\*Time + Baseline\\*Time.","timeFrame":"Baseline, Week 24"},{"measure":"Mean Change From Baseline in Waist Circumference","description":"LS means were calculated using a MMRM model for post-baseline measures: Variable = Treatment\\*Time + Baseline BMI (\\< 36kg/m2 vs. \\>=36 kg/m2)\\*Time + Sex (Female vs. Male)\\*Time + Baseline\\*Time.","timeFrame":"Baseline, Week 48"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Participants must have a Body Mass Index (BMI) ) ≥30 and ≤50 kilograms per square meter (kg/m²), or ≥27 kg/m² and \\<30 kg/m², with at least one of the following comorbidities: hypertension, dyslipidemia, cardiovascular disease\n* Participants must be willing to learn how to self-inject study drug or receive an injection from a trained individual if visually impaired or with physical limitations, and follow study procedures for the duration of the study, including, but not limited to, follow lifestyle advice (for example, dietary changes and physical activity plan), maintain a study drug administration log, and complete required questionnaires\n\nExclusion Criteria:\n\n* Participants must not have type 1 or type 2 diabetes mellitus\n* Participants must not have had an increase or decrease in body weight \\> more than 5 kg (11 pounds) within the past 3 months\n* Participants must not have had surgery for obesity or plan to have such surgery during the study\n* Participants must not be using medications that promote weight loss or cause weight gain\n* Participants must not drink excessive amounts of alcohol (more than 14 units a week for women or more than 21 units a week for men)\n* Participants must not have used marijuana within the last 3 months.\n* Participants must not have heart attack, stroke, or hospitalization for congestive heart failure in the past 3 months\n* Participants must not have active cancer within the last 5 years\n* Participants must not have uncontrolled high blood pressure\n* Participants must not have liver disease other than non-alcoholic fatty liver disease\n* Participants must not have renal impairment with estimated glomerular filtration rate (eGFR) \\<45 mL/min/1.73 m2\n* Participants must not have a history of acute or chronic pancreatitis symptomatic gallbladder disease or documented human immunodeficiency virus infection\n* Participants must not have a major problem with depression or other mental illness within the last 2 years\n* Participants must not have family or personal history of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma (family is defined as a first degree relative)\n* Female participants must not be pregnant, breast-feeding, or intend to become pregnant or of childbearing potential and not using adequate contraceptive method (adequate contraceptive measures as required by local regulation or practice)","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)","affiliation":"Eli Lilly and Company","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Perseverance Research Center","city":"Scottsdale","state":"Arizona","zip":"85254","country":"United States","geoPoint":{"lat":33.50921,"lon":-111.89903}},{"facility":"Anaheim Clinical Trials, LLC","city":"Anaheim","state":"California","zip":"92801","country":"United States","geoPoint":{"lat":33.83529,"lon":-117.9145}},{"facility":"Valley Research","city":"Fresno","state":"California","zip":"93720","country":"United States","geoPoint":{"lat":36.74773,"lon":-119.77237}},{"facility":"Velocity Clinical Research, Huntington Park","city":"Huntington Park","state":"California","zip":"90255","country":"United States","geoPoint":{"lat":33.98168,"lon":-118.22507}},{"facility":"Velocity Clinical Research, Huntington Park","city":"Los Angeles","state":"California","zip":"90057","country":"United States","geoPoint":{"lat":34.05223,"lon":-118.24368}},{"facility":"Southern California Dermatology, Inc.","city":"Santa Ana","state":"California","zip":"92701","country":"United States","geoPoint":{"lat":33.74557,"lon":-117.86783}},{"facility":"Coastal Metabolic Research Centre","city":"Ventura","state":"California","zip":"93003","country":"United States","geoPoint":{"lat":34.27834,"lon":-119.29317}},{"facility":"Diablo Clinical Research, Inc.","city":"Walnut Creek","state":"California","zip":"94598","country":"United States","geoPoint":{"lat":37.90631,"lon":-122.06496}},{"facility":"East Coast Institute for Research, LLC","city":"Jacksonville","state":"Florida","zip":"32216","country":"United States","geoPoint":{"lat":30.33218,"lon":-81.65565}},{"facility":"Suncoast Clinical Research, Inc.","city":"New Port Richey","state":"Florida","zip":"34652","country":"United States","geoPoint":{"lat":28.24418,"lon":-82.71927}},{"facility":"Encore Medical Research - Weston","city":"Weston","state":"Florida","zip":"33331","country":"United States","geoPoint":{"lat":26.10037,"lon":-80.39977}},{"facility":"Springfield Diabetes & Endocrine Center","city":"Springfield","state":"Illinois","zip":"62711","country":"United States","geoPoint":{"lat":39.80172,"lon":-89.64371}},{"facility":"Cotton O'Neil Diabetes and Endocrinology Center","city":"Topeka","state":"Kansas","zip":"66606","country":"United States","geoPoint":{"lat":39.04833,"lon":-95.67804}},{"facility":"Tandem Clinical Research,LLC","city":"Marrero","state":"Louisiana","zip":"70072","country":"United States","geoPoint":{"lat":29.89937,"lon":-90.10035}},{"facility":"StudyMetrix Research","city":"City of Saint Peters","state":"Missouri","zip":"63303","country":"United States","geoPoint":{"lat":38.80033,"lon":-90.62651}},{"facility":"Amici Clinical Research LLC","city":"Raritan","state":"New Jersey","zip":"08869","country":"United States","geoPoint":{"lat":40.56955,"lon":-74.63294}},{"facility":"Intend Research, LLC","city":"Norman","state":"Oklahoma","zip":"73069","country":"United States","geoPoint":{"lat":35.22257,"lon":-97.43948}},{"facility":"Allegheny Endocrinology Associates","city":"Pittsburgh","state":"Pennsylvania","zip":"15212","country":"United States","geoPoint":{"lat":40.44062,"lon":-79.99589}},{"facility":"New Phase Research and Development","city":"Knoxville","state":"Tennessee","zip":"37909","country":"United States","geoPoint":{"lat":35.96064,"lon":-83.92074}},{"facility":"Texas Diabetes & Endocrinology, P.A.","city":"Austin","state":"Texas","zip":"78731","country":"United States","geoPoint":{"lat":30.26715,"lon":-97.74306}},{"facility":"Dallas Diabetes Research Center","city":"Dallas","state":"Texas","zip":"75230","country":"United States","geoPoint":{"lat":32.78306,"lon":-96.80667}},{"facility":"Juno Research","city":"Houston","state":"Texas","zip":"77054","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"Endocrine Ips, Pllc","city":"Houston","state":"Texas","zip":"77079","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"Southern Endocrinology Associates","city":"Mesquite","state":"Texas","zip":"75149","country":"United States","geoPoint":{"lat":32.7668,"lon":-96.59916}},{"facility":"Rainier Clinical Research Center","city":"Renton","state":"Washington","zip":"98057","country":"United States","geoPoint":{"lat":47.48288,"lon":-122.21707}},{"facility":"Private Practice - Dr. Paola Mansilla-Letelier","city":"Guaynabo","zip":"00970","country":"Puerto Rico","geoPoint":{"lat":18.35745,"lon":-66.111}},{"facility":"GCM Medical Group, PSC - Hato Rey Site","city":"San Juan","zip":"00917","country":"Puerto Rico","geoPoint":{"lat":18.46633,"lon":-66.10572}},{"facility":"San Juan City Hospital","city":"San Juan","zip":"00935","country":"Puerto Rico","geoPoint":{"lat":18.46633,"lon":-66.10572}}]},"referencesModule":{"references":[{"pmid":"42608321","type":"DERIVED","citation":"Ruotolo G, Harris C, Lin Y, Wilson JM, Pirro V, Duffin KL, Thomas MK, Hartman ML, Neill CO, Coskun T, Milicevic Z, Haupt A, Sattar N, Nicholls SJ. Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes. Diabetes Obes Metab. 2026 Aug 17. doi: 10.1111/dom.71200. Online ahead of print."},{"pmid":"41201783","type":"DERIVED","citation":"Kanu C, Clucas C, Skalicky A, Samuelson A, Goetz I, Neff LM, Boye KS, Karn H. Development and Content Evaluation of the Eating Behavior and Appetite Questionnaire (EBAQ) for Individuals with Obesity. Adv Ther. 2026 Jan;43(1):150-164. doi: 10.1007/s12325-025-03386-2. Epub 2025 Nov 7."},{"pmid":"38858523","type":"DERIVED","citation":"Sanyal AJ, Kaplan LM, Frias JP, Brouwers B, Wu Q, Thomas MK, Harris C, Schloot NC, Du Y, Mather KJ, Haupt A, Hartman ML. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024 Jul;30(7):2037-2048. doi: 10.1038/s41591-024-03018-2. Epub 2024 Jun 10."},{"pmid":"37366315","type":"DERIVED","citation":"Jastreboff AM, Kaplan LM, Frias JP, Wu Q, Du Y, Gurbuz S, Coskun T, Haupt A, Milicevic Z, Hartman ML; Retatrutide Phase 2 Obesity Trial Investigators. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med. 2023 Aug 10;389(6):514-526. doi: 10.1056/NEJMoa2301972. Epub 2023 Jun 26."}],"seeAlsoLinks":[{"label":"A Study of LY3437943 in Participants Who Have Obesity or Are Overweight","url":"https://trials.lillytrialguide.com/en-US/trial/36s0UdwlFjVCXwfbif2fkc"}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.","infoTypes":["STUDY_PROTOCOL","SAP","CSR"],"timeFrame":"Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.","accessCriteria":"A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.","url":"https://vivli.org/"}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Four maintenance doses of LY3437943 were evaluated in the trial: 1, 4, 8, and 12 milligrams (mg). Dose escalation to improve gastrointestinal (GI) tolerability occured in certain treatment groups up to Week 12 by increasing the volume of administered study drug (or placebo) during the 48-week double-blind, placebo-controlled treatment period.","groups":[{"id":"FG000","title":"Placebo","description":"Participants received placebo matched to LY3437943 administered as subcutaneous (SC) injection once-weekly (QW)."},{"id":"FG001","title":"1 mg LY3437943","description":"Participants received 1 mg LY3437943 administered as SC injection QW."},{"id":"FG002","title":"4 mg LY3437943 (2 mg)","description":"Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 administered as SC injection QW."},{"id":"FG003","title":"4 mg LY3437943","description":"Participants received 4 mg LY3437943 administered as SC injection QW."},{"id":"FG004","title":"8 mg LY3437943 (2 mg)","description":"Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 and then 8 mg LY3437943 administered as SC injection QW."},{"id":"FG005","title":"8 mg LY3437943 (4 mg)","description":"Participants received 4 mg LY3437943 starting dose followed by 8 mg LY3437943 administered as SC injection QW."},{"id":"FG006","title":"12 mg LY3437943 (2 mg)","description":"Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943, 8 mg LY3437943 and then 12 mg LY3437943 administered as SC injection QW."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"70"},{"groupId":"FG001","numSubjects":"69"},{"groupId":"FG002","numSubjects":"33"},{"groupId":"FG003","numSubjects":"34"},{"groupId":"FG004","numSubjects":"35"},{"groupId":"FG005","numSubjects":"35"},{"groupId":"FG006","numSubjects":"62"}]},{"type":"Received at Least One Dose of Study Drug","achievements":[{"groupId":"FG000","numSubjects":"70"},{"groupId":"FG001","numSubjects":"69"},{"groupId":"FG002","numSubjects":"33"},{"groupId":"FG003","numSubjects":"33"},{"groupId":"FG004","numSubjects":"35"},{"groupId":"FG005","numSubjects":"35"},{"groupId":"FG006","numSubjects":"62"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"50"},{"groupId":"FG001","numSubjects":"60"},{"groupId":"FG002","numSubjects":"26"},{"groupId":"FG003","numSubjects":"26"},{"groupId":"FG004","numSubjects":"30"},{"groupId":"FG005","numSubjects":"29"},{"groupId":"FG006","numSubjects":"54"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"20"},{"groupId":"FG001","numSubjects":"9"},{"groupId":"FG002","numSubjects":"7"},{"groupId":"FG003","numSubjects":"8"},{"groupId":"FG004","numSubjects":"5"},{"groupId":"FG005","numSubjects":"6"},{"groupId":"FG006","numSubjects":"8"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"1"},{"groupId":"FG005","numSubjects":"1"},{"groupId":"FG006","numSubjects":"2"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"7"},{"groupId":"FG002","numSubjects":"5"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"2"},{"groupId":"FG005","numSubjects":"4"},{"groupId":"FG006","numSubjects":"4"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"13"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"4"},{"groupId":"FG004","numSubjects":"2"},{"groupId":"FG005","numSubjects":"1"},{"groupId":"FG006","numSubjects":"2"}]},{"type":"Randomized but Never Treated","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"}]},{"type":"Inadvertent Enrollment","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"}]},{"type":"Site Closure","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"All randomized participants.","groups":[{"id":"BG000","title":"Placebo","description":"Participants received placebo matched to LY3437943 administered as SC injection QW."},{"id":"BG001","title":"1 mg LY3437943","description":"Participants received 1 mg LY3437943 administered as SC injection QW."},{"id":"BG002","title":"4 mg LY3437943 (2 mg)","description":"Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 administered as SC injection QW."},{"id":"BG003","title":"4 mg LY3437943","description":"Participants received 4 mg LY3437943 administered as SC injection QW."},{"id":"BG004","title":"8 mg LY3437943 (2 mg)","description":"Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 and then 8 mg LY3437943 administered as SC injection QW."},{"id":"BG005","title":"8 mg LY343794 (4 mg)","description":"Participants received 4 mg LY3437943 starting dose followed by 8 mg LY3437943 administered as SC injection QW."},{"id":"BG006","title":"12 mg LY3437943 (2 mg)","description":"Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943, 8 mg LY3437943 and then 12 mg LY3437943 administered as SC injection QW."},{"id":"BG007","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"70"},{"groupId":"BG001","value":"69"},{"groupId":"BG002","value":"33"},{"groupId":"BG003","value":"34"},{"groupId":"BG004","value":"35"},{"groupId":"BG005","value":"35"},{"groupId":"BG006","value":"62"},{"groupId":"BG007","value":"338"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"48.00","spread":"12.54"},{"groupId":"BG001","value":"50.60","spread":"13.30"},{"groupId":"BG002","value":"50.80","spread":"11.88"},{"groupId":"BG003","value":"46.80","spread":"14.10"},{"groupId":"BG004","value":"46.10","spread":"13.52"},{"groupId":"BG005","value":"48.70","spread":"11.14"},{"groupId":"BG006","value":"45.80","spread":"12.18"},{"groupId":"BG007","value":"48.20","spread":"12.73"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"34"},{"groupId":"BG001","value":"33"},{"groupId":"BG002","value":"16"},{"groupId":"BG003","value":"16"},{"groupId":"BG004","value":"17"},{"groupId":"BG005","value":"17"},{"groupId":"BG006","value":"30"},{"groupId":"BG007","value":"163"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"36"},{"groupId":"BG001","value":"36"},{"groupId":"BG002","value":"17"},{"groupId":"BG003","value":"18"},{"groupId":"BG004","value":"18"},{"groupId":"BG005","value":"18"},{"groupId":"BG006","value":"32"},{"groupId":"BG007","value":"175"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"22"},{"groupId":"BG001","value":"23"},{"groupId":"BG002","value":"9"},{"groupId":"BG003","value":"14"},{"groupId":"BG004","value":"15"},{"groupId":"BG005","value":"12"},{"groupId":"BG006","value":"22"},{"groupId":"BG007","value":"117"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"47"},{"groupId":"BG001","value":"46"},{"groupId":"BG002","value":"24"},{"groupId":"BG003","value":"20"},{"groupId":"BG004","value":"20"},{"groupId":"BG005","value":"23"},{"groupId":"BG006","value":"40"},{"groupId":"BG007","value":"220"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"1"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"1"},{"groupId":"BG007","value":"2"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"1"},{"groupId":"BG007","value":"4"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"1"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"4"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"2"},{"groupId":"BG007","value":"27"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"59"},{"groupId":"BG001","value":"61"},{"groupId":"BG002","value":"29"},{"groupId":"BG003","value":"30"},{"groupId":"BG004","value":"30"},{"groupId":"BG005","value":"33"},{"groupId":"BG006","value":"56"},{"groupId":"BG007","value":"298"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"2"},{"groupId":"BG007","value":"5"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"1"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"70"},{"groupId":"BG001","value":"69"},{"groupId":"BG002","value":"33"},{"groupId":"BG003","value":"34"},{"groupId":"BG004","value":"35"},{"groupId":"BG005","value":"35"},{"groupId":"BG006","value":"62"},{"groupId":"BG007","value":"338"}]}]}]},{"title":"Baseline Body Weight","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"kilograms (kg)","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"109.21","spread":"20.88"},{"groupId":"BG001","value":"106.36","spread":"19.84"},{"groupId":"BG002","value":"108.04","spread":"26.31"},{"groupId":"BG003","value":"107.01","spread":"21.29"},{"groupId":"BG004","value":"106.50","spread":"21.55"},{"groupId":"BG005","value":"108.63","spread":"20.88"},{"groupId":"BG006","value":"107.97","spread":"21.69"},{"groupId":"BG007","value":"107.73","spread":"21.35"}]}]}]},{"title":"Baseline Body Mass Index (BMI)","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"kilograms per meter squared (kg/m^2)","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"37.31","spread":"5.90"},{"groupId":"BG001","value":"37.49","spread":"5.85"},{"groupId":"BG002","value":"37.27","spread":"5.87"},{"groupId":"BG003","value":"37.39","spread":"4.66"},{"groupId":"BG004","value":"37.37","spread":"6.04"},{"groupId":"BG005","value":"36.96","spread":"5.49"},{"groupId":"BG006","value":"37.42","spread":"5.98"},{"groupId":"BG007","value":"37.34","spread":"5.71"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Mean Percent Change From Baseline in Body Weight","description":"Least squares (LS) means were calculated using a mixed-effects model for repeated measures (MMRM) for post-baseline measures: Variable = Treatment\\*Time + Baseline BMI (\\< 36kg/m2 vs. \\>=36 kg/m2)\\*Time + Sex (Female vs. Male)\\*Time + Baseline\\*Time.","populationDescription":"All randomized participants who had baseline and at least one post-baseline body weight value, excluding participants discontinuing study drug due to inadvertent enrollment and data after discontinuation of study drug.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"percent change","timeFrame":"Baseline, Week 24","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo matched to LY3437943 administered as SC injection QW."},{"id":"OG001","title":"1 mg LY3437943","description":"Participants received 1 mg LY3437943 administered as SC injection QW."},{"id":"OG002","title":"4 mg LY3437943 (2 mg)","description":"Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 administered as SC injection QW."},{"id":"OG003","title":"4 mg LY3437943","description":"Participants received 4 mg LY3437943 administered as SC injection QW."},{"id":"OG004","title":"8 mg LY3437943 (2 mg)","description":"Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 and then 8 mg LY3437943 administered as SC injection QW."},{"id":"OG005","title":"8 mg LY3437943 (4 mg)","description":"Participants received 4 mg LY3437943 starting dose followed by 8 mg LY3437943 administered as SC injection QW."},{"id":"OG006","title":"12 mg LY3437943 (2 mg)","description":"Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943, 8 mg LY3437943 and then 12 mg LY3437943 administered as SC injection QW."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"68"},{"groupId":"OG001","value":"69"},{"groupId":"OG002","value":"33"},{"groupId":"OG003","value":"33"},{"groupId":"OG004","value":"35"},{"groupId":"OG005","value":"35"},{"groupId":"OG006","value":"62"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.55","spread":"0.54"},{"groupId":"OG001","value":"-7.18","spread":"0.67"},{"groupId":"OG002","value":"-12.00","spread":"0.71"},{"groupId":"OG003","value":"-13.80","spread":"0.97"},{"groupId":"OG004","value":"-16.64","spread":"0.74"},{"groupId":"OG005","value":"-18.26","spread":"0.95"},{"groupId":"OG006","value":"-17.39","spread":"0.69"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean difference (Final Values)","paramValue":"-5.64","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-7.34","ciUpperLimit":"-3.94"},{"groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean difference (Final Values)","paramValue":"-10.45","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-12.21","ciUpperLimit":"-8.70"},{"groupIds":["OG000","OG003"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean difference (Final Values)","paramValue":"-12.25","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-14.42","ciUpperLimit":"-10.08"},{"groupIds":["OG000","OG004"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean difference (Final Values)","paramValue":"-15.10","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-16.90","ciUpperLimit":"-13.30"},{"groupIds":["OG000","OG005"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean difference (Final Values)","paramValue":"-16.72","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-18.86","ciUpperLimit":"-14.58"},{"groupIds":["OG000","OG006"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean difference (Final Values)","paramValue":"-15.85","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-17.57","ciUpperLimit":"-14.13"}]},{"type":"SECONDARY","title":"Mean Percent Change From Baseline in Body Weight","description":"LS means were calculated using a MMRM model for post-baseline measures: Variable = Treatment\\*Time + Baseline BMI (\\< 36kg/m2 vs. \\>=36 kg/m2)\\*Time + Sex (Female vs. Male)\\*Time + Baseline\\*Time.","populationDescription":"All randomized participants who had baseline and at least one post-baseline body weight value, excluding participants discontinuing study drug due to inadvertent enrollment and data after discontinuation of study drug.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"percent change","timeFrame":"Baseline, Week 48","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo matched to LY3437943 administered as SC injection QW."},{"id":"OG001","title":"1 mg LY3437943","description":"Participants received 1 mg LY3437943 administered as SC injection QW."},{"id":"OG002","title":"4 mg LY3437943 (2 mg)","description":"Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 administered as SC injection QW."},{"id":"OG003","title":"4 mg LY3437943","description":"Participants received 4 mg LY3437943 administered as SC injection QW."},{"id":"OG004","title":"8 mg LY3437943 (2 mg)","description":"Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 and then 8 mg LY3437943 administered as SC injection QW."},{"id":"OG005","title":"8 mg LY3437943 (4 mg)","description":"Participants received 4 mg LY3437943 starting dose followed by 8 mg LY3437943 administered as SC injection QW."},{"id":"OG006","title":"12 mg LY3437943 (2 mg)","description":"Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943, 8 mg LY3437943 and then 12 mg LY3437943 administered as SC injection QW."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"68"},{"groupId":"OG001","value":"69"},{"groupId":"OG002","value":"33"},{"groupId":"OG003","value":"33"},{"groupId":"OG004","value":"35"},{"groupId":"OG005","value":"35"},{"groupId":"OG006","value":"62"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.11","spread":"0.73"},{"groupId":"OG001","value":"-8.67","spread":"0.95"},{"groupId":"OG002","value":"-16.32","spread":"1.58"},{"groupId":"OG003","value":"-17.83","spread":"1.53"},{"groupId":"OG004","value":"-21.72","spread":"1.41"},{"groupId":"OG005","value":"-23.88","spread":"1.51"},{"groupId":"OG006","value":"-24.22","spread":"1.24"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean difference (Final Values)","paramValue":"-6.57","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-8.94","ciUpperLimit":"-4.20"},{"groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean difference (Final Values)","paramValue":"-14.21","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-17.64","ciUpperLimit":"-10.78"},{"groupIds":["OG000","OG003"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean difference (Final Values)","paramValue":"-15.72","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-19.05","ciUpperLimit":"-12.40"},{"groupIds":["OG000","OG004"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean difference (Final Values)","paramValue":"-19.62","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-22.73","ciUpperLimit":"-16.51"},{"groupIds":["OG000","OG005"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean difference (Final Values)","paramValue":"-21.78","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-25.05","ciUpperLimit":"-18.51"},{"groupIds":["OG000","OG006"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean difference (Final Values)","paramValue":"-22.11","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-24.92","ciUpperLimit":"-19.31"}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieve ≥ 5% Body Weight Reduction","description":"Percentage of participants who achieve ≥ 5% body weight reduction in LY3437943 relative to placebo. Estimated percentage was determined by logistic regression model with an intercept term, treatment group, baseline BMI stratum \\[\\<36 kilograms per square meter (kg/m2), ≥36 kg/m2\\] and sex \\[female, male\\] as fixed effects, and baseline body weight as a covariate.","populationDescription":"All randomized participants who had baseline and at least one post-baseline value for ≥ 5% body weight reduction excluding participants discontinuing study drug due to inadvertent enrollment and data after discontinuation of study drug.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Week 24","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo matched to LY3437943 administered as SC injection QW."},{"id":"OG001","title":"1 mg LY3437943","description":"Participants received 1 mg LY3437943 administered as SC injection QW."},{"id":"OG002","title":"4 mg LY3437943 (2 mg)","description":"Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 administered as SC injection QW."},{"id":"OG003","title":"4 mg LY3437943","description":"Participants received 4 mg LY3437943 administered as SC injection QW."},{"id":"OG004","title":"8 mg LY3437943 (2 mg)","description":"Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 and then 8 mg LY3437943 administered as SC injection QW."},{"id":"OG005","title":"8 mg LY3437943 (4 mg)","description":"Participants received 4 mg LY3437943 starting dose followed by 8 mg LY3437943 administered as SC injection QW."},{"id":"OG006","title":"12 mg LY3437943 (2 mg)","description":"Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943, 8 mg LY3437943 and then 12 mg LY3437943 administered as SC injection QW."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"68"},{"groupId":"OG001","value":"69"},{"groupId":"OG002","value":"33"},{"groupId":"OG003","value":"33"},{"groupId":"OG004","value":"35"},{"groupId":"OG005","value":"35"},{"groupId":"OG006","value":"62"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"59"},{"groupId":"OG002","value":"87"},{"groupId":"OG003","value":"94"},{"groupId":"OG004","value":"100"},{"groupId":"OG005","value":"100"},{"groupId":"OG006","value":"97"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"Regression, Logistic","paramType":"Risk Difference (RD)","paramValue":"33","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"17","ciUpperLimit":"49"},{"groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"Regression, Logistic","paramType":"Risk Difference (RD)","paramValue":"61","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"45","ciUpperLimit":"77"},{"groupIds":["OG000","OG003"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"Regression, Logistic","paramType":"Risk Difference (RD)","paramValue":"68","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"54","ciUpperLimit":"81"},{"groupIds":["OG000","OG004"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"Regression, Logistic","paramType":"Risk Difference (RD)","paramValue":"74","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"63","ciUpperLimit":"85"},{"groupIds":["OG000","OG005"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"Regression, Logistic","paramType":"Risk Difference (RD)","paramValue":"74","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"63","ciUpperLimit":"85"},{"groupIds":["OG000","OG006"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"Regression, Logistic","paramType":"Risk Difference (RD)","paramValue":"71","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"59","ciUpperLimit":"82"}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieve ≥ 5% Body Weight Reduction","description":"Percentage of participants who achieve ≥ 5% body weight reduction in LY3437943 relative to placebo. Estimated percentage was determined by logistic regression model with an intercept term, treatment group, baseline BMI stratum \\[\\<36 kg/m2, ≥36 kg/m2\\] and sex \\[female, male\\] as fixed effects, and baseline body weight as a covariate.","populationDescription":"All randomized participants who had baseline and at least one post-baseline value for ≥ 5% body weight reduction, excluding participants discontinuing study drug due to inadvertent enrollment and data after discontinuation of study drug.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Week 48","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo matched to LY3437943 administered as SC injection QW."},{"id":"OG001","title":"1 mg LY3437943","description":"Participants received 1 mg LY3437943 administered as SC injection QW."},{"id":"OG002","title":"4 mg LY3437943 (2 mg)","description":"Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 administered as SC injection QW."},{"id":"OG003","title":"4 mg LY3437943","description":"Participants received 4 mg LY3437943 administered as SC injection QW."},{"id":"OG004","title":"8 mg LY3437943 (2 mg)","description":"Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 and then 8 mg LY3437943 administered as SC injection QW."},{"id":"OG005","title":"8 mg LY3437943 (4 mg)","description":"Participants received 4 mg LY3437943 starting dose followed by 8 mg LY3437943 administered as SC injection QW."},{"id":"OG006","title":"12 mg LY3437943 (2 mg)","description":"Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943, 8 mg LY3437943 and then 12 mg LY3437943 administered as SC injection QW."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"68"},{"groupId":"OG001","value":"69"},{"groupId":"OG002","value":"33"},{"groupId":"OG003","value":"33"},{"groupId":"OG004","value":"35"},{"groupId":"OG005","value":"35"},{"groupId":"OG006","value":"62"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"64"},{"groupId":"OG002","value":"87"},{"groupId":"OG003","value":"97"},{"groupId":"OG004","value":"100"},{"groupId":"OG005","value":"100"},{"groupId":"OG006","value":"100"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"Regression, Logistic","paramType":"Risk Difference (RD)","paramValue":"37","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"20","ciUpperLimit":"54"},{"groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"Regression, Logistic","paramType":"Risk Difference (RD)","paramValue":"60","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"44","ciUpperLimit":"76"},{"groupIds":["OG000","OG003"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"Regression, Logistic","paramType":"Risk Difference (RD)","paramValue":"70","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"57","ciUpperLimit":"83"},{"groupIds":["OG000","OG004"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"Regression, Logistic","paramType":"Risk Difference (RD)","paramValue":"73","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"62","ciUpperLimit":"84"},{"groupIds":["OG000","OG005"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"Regression, Logistic","paramType":"Risk Difference (RD)","paramValue":"73","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"62","ciUpperLimit":"84"},{"groupIds":["OG000","OG006"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"Regression, Logistic","paramType":"Risk Difference (RD)","paramValue":"73","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"67","ciUpperLimit":"84"}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieve ≥ 10% Body Weight Reduction","description":"Percentage of participants who achieve ≥ 10% body weight reduction in LY3437943 relative to placebo. Estimated percentage was determined by logistic regression model with an intercept term, treatment group, baseline BMI stratum \\[\\<36 kg/m2, ≥36 kg/m2\\] and sex \\[female, male\\] as fixed effects, and baseline body weight as a covariate.","populationDescription":"All randomized participants who had baseline and at least one post-baseline value for ≥ 10% body weight reduction, excluding participants discontinuing study drug due to inadvertent enrollment and data after discontinuation of study drug.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Week 24","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo matched to LY3437943 administered as SC injection QW."},{"id":"OG001","title":"1 mg LY3437943","description":"Participants received 1 mg LY3437943 administered as SC injection QW."},{"id":"OG002","title":"4 mg LY3437943 (2 mg)","description":"Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 administered as SC injection QW."},{"id":"OG003","title":"4 mg LY3437943","description":"Participants received 4 mg LY3437943 administered as SC injection QW."},{"id":"OG004","title":"8 mg LY3437943 (2 mg)","description":"Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 and then 8 mg LY3437943 administered as SC injection QW."},{"id":"OG005","title":"8 mg LY3437943 (4 mg)","description":"Participants received 4 mg LY3437943 starting dose followed by 8 mg LY3437943 administered as SC injection QW."},{"id":"OG006","title":"12 mg LY3437943 (2 mg)","description":"Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943, 8 mg LY3437943 and then 12 mg LY3437943 administered as SC injection QW."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"68"},{"groupId":"OG001","value":"69"},{"groupId":"OG002","value":"33"},{"groupId":"OG003","value":"33"},{"groupId":"OG004","value":"35"},{"groupId":"OG005","value":"35"},{"groupId":"OG006","value":"62"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"25"},{"groupId":"OG002","value":"59"},{"groupId":"OG003","value":"72"},{"groupId":"OG004","value":"83"},{"groupId":"OG005","value":"94"},{"groupId":"OG006","value":"90"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"Regression, Logistic","paramType":"Risk Difference (RD)","paramValue":"22","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"11","ciUpperLimit":"33"},{"groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"Regression, Logistic","paramType":"Risk Difference (RD)","paramValue":"56","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"38","ciUpperLimit":"73"},{"groupIds":["OG000","OG003"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"Regression, Logistic","paramType":"Risk Difference (RD)","paramValue":"69","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"53","ciUpperLimit":"85"},{"groupIds":["OG000","OG004"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"Regression, Logistic","paramType":"Risk Difference (RD)","paramValue":"80","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"66","ciUpperLimit":"93"},{"groupIds":["OG000","OG005"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"Regression, Logistic","paramType":"Risk Difference (RD)","paramValue":"91","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"83","ciUpperLimit":"100"},{"groupIds":["OG000","OG006"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"Regression, Logistic","paramType":"Risk Difference (RD)","paramValue":"87","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"78","ciUpperLimit":"96"}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieve ≥ 10% Body Weight Reduction","description":"Percentage of participants who achieve ≥ 10% body weight reduction in LY3437943 relative to placebo. Estimated percentage was determined by logistic regression model with an intercept term, treatment group, baseline BMI stratum \\[\\<36 kg/m2, ≥36 kg/m2\\] and sex \\[female, male\\] as fixed effects, and baseline body weight as a covariate.","populationDescription":"All randomized participants who had baseline and at least one post-baseline value for ≥ 10% body weight reduction, excluding participants discontinuing study drug due to inadvertent enrollment and data after discontinuation of study drug.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Week 48","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo matched to LY3437943 administered as SC injection QW."},{"id":"OG001","title":"1 mg LY3437943","description":"Participants received 1 mg LY3437943 administered as SC injection QW."},{"id":"OG002","title":"4 mg LY3437943 (2 mg)","description":"Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 administered as SC injection QW."},{"id":"OG003","title":"4 mg LY3437943","description":"Participants received 4 mg LY3437943 administered as SC injection QW."},{"id":"OG004","title":"8 mg LY3437943 (2 mg)","description":"Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 and then 8 mg LY3437943 administered as SC injection QW."},{"id":"OG005","title":"8 mg LY3437943 (4 mg)","description":"Participants received 4 mg LY3437943 starting dose followed by 8 mg LY3437943 administered as SC injection QW."},{"id":"OG006","title":"12 mg LY3437943 (2 mg)","description":"Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943, 8 mg LY3437943 and then 12 mg LY3437943 administered as SC injection QW."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"68"},{"groupId":"OG001","value":"69"},{"groupId":"OG002","value":"33"},{"groupId":"OG003","value":"33"},{"groupId":"OG004","value":"35"},{"groupId":"OG005","value":"35"},{"groupId":"OG006","value":"62"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"27"},{"groupId":"OG002","value":"73"},{"groupId":"OG003","value":"76"},{"groupId":"OG004","value":"90"},{"groupId":"OG005","value":"91"},{"groupId":"OG006","value":"93"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.008","statisticalMethod":"Regression, Logistic","paramType":"Risk Difference (RD)","paramValue":"18","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"5","ciUpperLimit":"31"},{"groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"Regression, Logistic","paramType":"Risk Difference (RD)","paramValue":"64","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"48","ciUpperLimit":"81"},{"groupIds":["OG000","OG003"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"Regression, Logistic","paramType":"Risk Difference (RD)","paramValue":"67","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"51","ciUpperLimit":"84"},{"groupIds":["OG000","OG004"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"Regression, Logistic","paramType":"Risk Difference (RD)","paramValue":"81","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"69","ciUpperLimit":"94"},{"groupIds":["OG000","OG005"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"Regression, Logistic","paramType":"Risk Difference (RD)","paramValue":"82","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"71","ciUpperLimit":"94"},{"groupIds":["OG000","OG006"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"Regression, Logistic","paramType":"Risk Difference (RD)","paramValue":"84","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"74","ciUpperLimit":"94"}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieve ≥ 15% Body Weight Reduction","description":"Percentage of participants who achieve ≥ 15% body weight reduction in LY3437943 relative to placebo. Estimated percentage was determined by logistic regression model with an intercept term, treatment group, baseline BMI stratum \\[\\<36 kg/m2, ≥36 kg/m2\\] and sex \\[female, male\\] as fixed effects, and baseline body weight as a covariate.","populationDescription":"All randomized participants who had baseline and at least one post-baseline value for ≥ 15% body weight reduction, excluding participants discontinuing study drug due to inadvertent enrollment and data after discontinuation of study drug.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Week 24","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo matched to LY3437943 administered as SC injection QW."},{"id":"OG001","title":"1 mg LY3437943","description":"Participants received 1 mg LY3437943 administered as SC injection QW."},{"id":"OG002","title":"4 mg LY3437943 (2 mg)","description":"Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 administered as SC injection QW."},{"id":"OG003","title":"4 mg LY3437943","description":"Participants received 4 mg LY3437943 administered as SC injection QW."},{"id":"OG004","title":"8 mg LY3437943 (2 mg)","description":"Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 and then 8 mg LY3437943 administered as SC injection QW."},{"id":"OG005","title":"8 mg LY3437943 (4 mg)","description":"Participants received 4 mg LY3437943 starting dose followed by 8 mg LY3437943 administered as SC injection QW."},{"id":"OG006","title":"12 mg LY3437943 (2 mg)","description":"Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943, 8 mg LY3437943 and then 12 mg LY3437943 administered as SC injection QW."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"68"},{"groupId":"OG001","value":"69"},{"groupId":"OG002","value":"33"},{"groupId":"OG003","value":"33"},{"groupId":"OG004","value":"35"},{"groupId":"OG005","value":"35"},{"groupId":"OG006","value":"62"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"29"},{"groupId":"OG003","value":"44"},{"groupId":"OG004","value":"51"},{"groupId":"OG005","value":"68"},{"groupId":"OG006","value":"70"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.029","statisticalMethod":"Regression, Logistic","paramType":"Risk Difference (RD)","paramValue":"9","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1","ciUpperLimit":"17"},{"groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"Regression, Logistic","paramType":"Risk Difference (RD)","paramValue":"27","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"11","ciUpperLimit":"43"},{"groupIds":["OG000","OG003"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"Regression, Logistic","paramType":"Risk Difference (RD)","paramValue":"43","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"26","ciUpperLimit":"60"},{"groupIds":["OG000","OG004"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"Regression, Logistic","paramType":"Risk Difference (RD)","paramValue":"49","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"33","ciUpperLimit":"66"},{"groupIds":["OG000","OG005"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"Regression, Logistic","paramType":"Risk Difference (RD)","paramValue":"67","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"51","ciUpperLimit":"83"},{"groupIds":["OG000","OG006"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"Regression, Logistic","paramType":"Risk Difference (RD)","paramValue":"68","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"56","ciUpperLimit":"80"}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieve ≥ 15% Body Weight Reduction","description":"Percentage of participants who achieve ≥ 15% body weight reduction in LY3437943 relative to placebo. Estimated percentage was determined by logistic regression model with an intercept term, treatment group, baseline BMI stratum \\[\\<36 kg/m2, ≥36 kg/m2\\] and sex \\[female, male\\] as fixed effects, and baseline body weight as a covariate.","populationDescription":"All randomized participants who had baseline and at least one post-baseline value for ≥ 15% body weight reduction, excluding participants discontinuing study drug due to inadvertent enrollment and data after discontinuation of study drug.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Week 48","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo matched to LY3437943 administered as SC injection QW."},{"id":"OG001","title":"1 mg LY3437943","description":"Participants received 1 mg LY3437943 administered as SC injection QW."},{"id":"OG002","title":"4 mg LY3437943 (2 mg)","description":"Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 administered as SC injection QW."},{"id":"OG003","title":"4 mg LY3437943","description":"Participants received 4 mg LY3437943 administered as SC injection QW."},{"id":"OG004","title":"8 mg LY3437943 (2 mg)","description":"Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 and then 8 mg LY3437943 administered as SC injection QW."},{"id":"OG005","title":"8 mg LY3437943 (4 mg)","description":"Participants received 4 mg LY3437943 starting dose followed by 8 mg LY3437943 administered as SC injection QW."},{"id":"OG006","title":"12 mg LY3437943 (2 mg)","description":"Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943, 8 mg LY3437943 and then 12 mg LY3437943 administered as SC injection QW."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"68"},{"groupId":"OG001","value":"69"},{"groupId":"OG002","value":"33"},{"groupId":"OG003","value":"33"},{"groupId":"OG004","value":"35"},{"groupId":"OG005","value":"35"},{"groupId":"OG006","value":"62"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"55"},{"groupId":"OG003","value":"64"},{"groupId":"OG004","value":"73"},{"groupId":"OG005","value":"77"},{"groupId":"OG006","value":"83"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.002","statisticalMethod":"Regression, Logistic","paramType":"Risk Difference (RD)","paramValue":"15","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"6","ciUpperLimit":"24"},{"groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"Regression, Logistic","paramType":"Risk Difference (RD)","paramValue":"53","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"36","ciUpperLimit":"70"},{"groupIds":["OG000","OG003"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"Regression, Logistic","paramType":"Risk Difference (RD)","paramValue":"63","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"47","ciUpperLimit":"79"},{"groupIds":["OG000","OG004"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"Regression, Logistic","paramType":"Risk Difference (RD)","paramValue":"71","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"55","ciUpperLimit":"87"},{"groupIds":["OG000","OG005"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"Regression, Logistic","paramType":"Risk Difference (RD)","paramValue":"75","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"62","ciUpperLimit":"89"},{"groupIds":["OG000","OG006"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"Regression, Logistic","paramType":"Risk Difference (RD)","paramValue":"82","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"71","ciUpperLimit":"92"}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Body Weight","description":"LS means were calculated using a MMRM model for post-baseline measures: Variable = Treatment\\*Time + Baseline BMI (\\< 36kg/m2 vs. \\>=36 kg/m2)\\*Time + Sex (Female vs. Male)\\*Time + Baseline\\*Time.","populationDescription":"All randomized participants who had baseline and at least one post-baseline value for body weight, excluding participants discontinuing study drug due to inadvertent enrollment and data after discontinuation of study drug.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"kilograms (kg)","timeFrame":"Baseline, Week 24","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo matched to LY3437943 administered as SC injection QW."},{"id":"OG001","title":"1 mg LY3437943","description":"Participants received 1 mg LY3437943 administered as SC injection QW."},{"id":"OG002","title":"4 mg LY3437943 (2 mg)","description":"Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 administered as SC injection QW."},{"id":"OG003","title":"4 mg LY3437943","description":"Participants received 4 mg LY3437943 administered as SC injection QW."},{"id":"OG004","title":"8 mg LY3437943 (2 mg)","description":"Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 and then 8 mg LY3437943 administered as SC injection QW."},{"id":"OG005","title":"8 mg LY3437943 (4 mg)","description":"Participants received 4 mg LY3437943 starting dose followed by 8 mg LY3437943 administered as SC injection QW."},{"id":"OG006","title":"12 mg LY3437943 (2 mg)","description":"Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943, 8 mg LY3437943 and then 12 mg LY3437943 administered as SC injection QW."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"68"},{"groupId":"OG001","value":"69"},{"groupId":"OG002","value":"33"},{"groupId":"OG003","value":"33"},{"groupId":"OG004","value":"35"},{"groupId":"OG005","value":"35"},{"groupId":"OG006","value":"62"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.27","spread":"0.63"},{"groupId":"OG001","value":"-7.72","spread":"0.73"},{"groupId":"OG002","value":"-12.59","spread":"0.81"},{"groupId":"OG003","value":"-14.79","spread":"1.09"},{"groupId":"OG004","value":"-17.70","spread":"0.79"},{"groupId":"OG005","value":"-19.75","spread":"1.08"},{"groupId":"OG006","value":"-18.53","spread":"0.71"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean difference (Final Values)","paramValue":"-6.46","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-8.36","ciUpperLimit":"-4.56"},{"groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean difference (Final Values)","paramValue":"-11.32","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-13.34","ciUpperLimit":"-9.30"},{"groupIds":["OG000","OG003"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean difference (Final Values)","paramValue":"-13.52","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-15.99","ciUpperLimit":"-11.05"},{"groupIds":["OG000","OG004"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean difference (Final Values)","paramValue":"-16.43","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-18.41","ciUpperLimit":"-14.45"},{"groupIds":["OG000","OG005"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean difference (Final Values)","paramValue":"-18.48","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-20.93","ciUpperLimit":"-16.04"},{"groupIds":["OG000","OG006"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean difference (Final Values)","paramValue":"-17.26","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-19.11","ciUpperLimit":"-15.40"}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Body Weight","description":"LS means were calculated using a MMRM model for post-baseline measures: Variable = Treatment\\*Time + Baseline BMI (\\< 36kg/m2 vs. \\>=36 kg/m2)\\*Time + Sex (Female vs. Male)\\*Time + Baseline\\*Time.","populationDescription":"All randomized participants who had baseline and at least one post-baseline value for body weight, excluding participants discontinuing study drug due to inadvertent enrollment and data after discontinuation of study drug.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"kg","timeFrame":"Baseline, Week 48","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo matched to LY3437943 administered as SC injection QW."},{"id":"OG001","title":"1 mg LY3437943","description":"Participants received 1 mg LY3437943 administered as SC injection QW."},{"id":"OG002","title":"4 mg LY3437943 (2 mg)","description":"Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 administered as SC injection QW."},{"id":"OG003","title":"4 mg LY3437943","description":"Participants received 4 mg LY3437943 administered as SC injection QW."},{"id":"OG004","title":"8 mg LY3437943 (2 mg)","description":"Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 and then 8 mg LY3437943 administered as SC injection QW."},{"id":"OG005","title":"8 mg LY3437943 (4 mg)","description":"Participants received 4 mg LY3437943 starting dose followed by 8 mg LY3437943 administered as SC injection QW."},{"id":"OG006","title":"12 mg LY3437943 (2 mg)","description":"Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943, 8 mg LY3437943 and then 12 mg LY3437943 administered as SC injection QW."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"68"},{"groupId":"OG001","value":"69"},{"groupId":"OG002","value":"33"},{"groupId":"OG003","value":"33"},{"groupId":"OG004","value":"35"},{"groupId":"OG005","value":"35"},{"groupId":"OG006","value":"62"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.84","spread":"0.83"},{"groupId":"OG001","value":"-9.37","spread":"1.06"},{"groupId":"OG002","value":"-17.32","spread":"1.78"},{"groupId":"OG003","value":"-19.13","spread":"1.80"},{"groupId":"OG004","value":"-23.52","spread":"1.61"},{"groupId":"OG005","value":"-25.88","spread":"1.68"},{"groupId":"OG006","value":"-26.17","spread":"1.33"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean difference (Final Values)","paramValue":"-7.53","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-10.18","ciUpperLimit":"-4.88"},{"groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean difference (Final Values)","paramValue":"-15.48","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-19.35","ciUpperLimit":"-11.60"},{"groupIds":["OG000","OG003"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean difference (Final Values)","paramValue":"-17.29","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-21.19","ciUpperLimit":"-13.39"},{"groupIds":["OG000","OG004"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean difference (Final Values)","paramValue":"-21.69","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-25.25","ciUpperLimit":"-18.12"},{"groupIds":["OG000","OG005"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean difference (Final Values)","paramValue":"-24.04","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-27.72","ciUpperLimit":"-20.36"},{"groupIds":["OG000","OG006"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean difference (Final Values)","paramValue":"-24.34","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-27.40","ciUpperLimit":"-21.27"}]},{"type":"SECONDARY","title":"Mean Change From Baseline in BMI","description":"LS means were calculated using a MMRM model for post-baseline measures: Variable = Treatment\\*Time + Baseline BMI (\\< 36kg/m2 vs. \\>=36 kg/m2)\\*Time + Sex (Female vs. Male)\\*Time + Baseline\\*Time.","populationDescription":"All randomized participants who had baseline and at least one post-baseline BMI value, excluding participants discontinuing study drug due to inadvertent enrollment and data after discontinuation of study drug.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"kg/m^2","timeFrame":"Baseline, Week 24","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo matched to LY3437943 administered as SC injection QW."},{"id":"OG001","title":"1 mg LY3437943","description":"Participants received 1 mg LY3437943 administered as SC injection QW."},{"id":"OG002","title":"4 mg LY3437943 (2 mg)","description":"Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 administered as SC injection QW."},{"id":"OG003","title":"4 mg LY3437943","description":"Participants received 4 mg LY3437943 administered as SC injection QW."},{"id":"OG004","title":"8 mg LY3437943 (2 mg)","description":"Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 and then 8 mg LY3437943 administered as SC injection QW."},{"id":"OG005","title":"8 mg LY3437943 (4 mg)","description":"Participants received 4 mg LY3437943 starting dose followed by 8 mg LY3437943 administered as SC injection QW."},{"id":"OG006","title":"12 mg LY3437943 (2 mg)","description":"Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943, 8 mg LY3437943 and then 12 mg LY3437943 administered as SC injection QW."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"68"},{"groupId":"OG001","value":"69"},{"groupId":"OG002","value":"33"},{"groupId":"OG003","value":"33"},{"groupId":"OG004","value":"35"},{"groupId":"OG005","value":"35"},{"groupId":"OG006","value":"62"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.49","spread":"0.21"},{"groupId":"OG001","value":"-2.64","spread":"0.26"},{"groupId":"OG002","value":"-4.47","spread":"0.28"},{"groupId":"OG003","value":"-5.13","spread":"0.36"},{"groupId":"OG004","value":"-6.15","spread":"0.27"},{"groupId":"OG005","value":"-6.84","spread":"0.36"},{"groupId":"OG006","value":"-6.44","spread":"0.25"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean difference (Final Values)","paramValue":"-2.15","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-2.80","ciUpperLimit":"-1.50"},{"groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean difference (Final Values)","paramValue":"-3.98","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-4.66","ciUpperLimit":"-3.29"},{"groupIds":["OG000","OG003"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean difference (Final Values)","paramValue":"-4.64","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-5.46","ciUpperLimit":"-3.82"},{"groupIds":["OG000","OG004"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean difference (Final Values)","paramValue":"-5.66","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-6.34","ciUpperLimit":"-4.99"},{"groupIds":["OG000","OG005"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean difference (Final Values)","paramValue":"-6.35","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-7.17","ciUpperLimit":"-5.53"},{"groupIds":["OG000","OG006"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean difference (Final Values)","paramValue":"-5.95","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-6.59","ciUpperLimit":"-5.32"}]},{"type":"SECONDARY","title":"Mean Change From Baseline in BMI","description":"LS means were calculated using a MMRM model for post-baseline measures: Variable = Treatment\\*Time + Baseline BMI (\\< 36kg/m2 vs. \\>=36 kg/m2)\\*Time + Sex (Female vs. Male)\\*Time + Baseline\\*Time.","populationDescription":"All randomized participants who had baseline and at least one post-baseline BMI value, excluding participants discontinuing study drug due to inadvertent enrollment and data after discontinuation of study drug.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"kg/m^2","timeFrame":"Baseline, Week 48","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo matched to LY3437943 administered as SC injection QW."},{"id":"OG001","title":"1 mg LY3437943","description":"Participants received 1 mg LY3437943 administered as SC injection QW."},{"id":"OG002","title":"4 mg LY3437943 (2 mg)","description":"Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 administered as SC injection QW."},{"id":"OG003","title":"4 mg LY3437943","description":"Participants received 4 mg LY3437943 administered as SC injection QW."},{"id":"OG004","title":"8 mg LY3437943 (2 mg)","description":"Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 and then 8 mg LY3437943 administered as SC injection QW."},{"id":"OG005","title":"8 mg LY3437943 (4 mg)","description":"Participants received 4 mg LY3437943 starting dose followed by 8 mg LY3437943 administered as SC injection QW."},{"id":"OG006","title":"12 mg LY3437943 (2 mg)","description":"Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943, 8 mg LY3437943 and then 12 mg LY3437943 administered as SC injection QW."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"68"},{"groupId":"OG001","value":"69"},{"groupId":"OG002","value":"33"},{"groupId":"OG003","value":"33"},{"groupId":"OG004","value":"35"},{"groupId":"OG005","value":"35"},{"groupId":"OG006","value":"62"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.72","spread":"0.29"},{"groupId":"OG001","value":"-3.22","spread":"0.37"},{"groupId":"OG002","value":"-6.14","spread":"0.65"},{"groupId":"OG003","value":"-6.67","spread":"0.59"},{"groupId":"OG004","value":"-8.12","spread":"0.55"},{"groupId":"OG005","value":"-9.02","spread":"0.57"},{"groupId":"OG006","value":"-9.14","spread":"0.46"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean difference (Final Values)","paramValue":"-2.50","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-3.42","ciUpperLimit":"-1.57"},{"groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean difference (Final Values)","paramValue":"-5.42","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-6.81","ciUpperLimit":"-4.03"},{"groupIds":["OG000","OG003"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean difference (Final Values)","paramValue":"-5.95","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-7.23","ciUpperLimit":"-4.67"},{"groupIds":["OG000","OG004"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean difference (Final Values)","paramValue":"-7.40","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-8.62","ciUpperLimit":"-6.18"},{"groupIds":["OG000","OG005"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean difference (Final Values)","paramValue":"-8.30","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-9.55","ciUpperLimit":"-7.05"},{"groupIds":["OG000","OG006"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean difference (Final Values)","paramValue":"-8.42","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-9.49","ciUpperLimit":"-7.35"}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Waist Circumference","description":"LS means were calculated using a MMRM model for post-baseline measures: Variable = Treatment\\*Time + Baseline BMI (\\< 36kg/m2 vs. \\>=36 kg/m2)\\*Time + Sex (Female vs. Male)\\*Time + Baseline\\*Time.","populationDescription":"All randomized participants who had baseline and at least one post-baseline waist circumference value, excluding participants discontinuing study drug due to inadvertent enrollment and data after discontinuation of study drug.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"centimeters (cm)","timeFrame":"Baseline, Week 24","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo matched to LY3437943 administered as SC injection QW."},{"id":"OG001","title":"1 mg LY3437943","description":"Participants received 1 mg LY3437943 administered as SC injection QW."},{"id":"OG002","title":"4 mg LY3437943 (2 mg)","description":"Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 administered as SC injection QW."},{"id":"OG003","title":"4 mg LY3437943","description":"Participants received 4 mg LY3437943 administered as SC injection QW."},{"id":"OG004","title":"8 mg LY3437943 (2 mg)","description":"Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 and then 8 mg LY3437943 administered as SC injection QW."},{"id":"OG005","title":"8 mg LY3437943 (4 mg)","description":"Participants received 4 mg LY3437943 starting dose followed by 8 mg LY3437943 administered as SC injection QW."},{"id":"OG006","title":"12 mg LY3437943 (2 mg)","description":"Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943, 8 mg LY3437943 and then 12 mg LY3437943 administered as SC injection QW."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"69"},{"groupId":"OG002","value":"32"},{"groupId":"OG003","value":"33"},{"groupId":"OG004","value":"35"},{"groupId":"OG005","value":"35"},{"groupId":"OG006","value":"62"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.60","spread":"0.80"},{"groupId":"OG001","value":"-5.43","spread":"0.94"},{"groupId":"OG002","value":"-10.33","spread":"1.05"},{"groupId":"OG003","value":"-12.55","spread":"1.00"},{"groupId":"OG004","value":"-13.74","spread":"1.04"},{"groupId":"OG005","value":"-14.99","spread":"0.98"},{"groupId":"OG006","value":"-14.33","spread":"0.86"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.022","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean difference (Final Values)","paramValue":"-2.82","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-5.23","ciUpperLimit":"-0.41"},{"groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean difference (Final Values)","paramValue":"-7.73","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-10.32","ciUpperLimit":"-5.13"},{"groupIds":["OG000","OG003"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean difference (Final Values)","paramValue":"-9.95","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-12.47","ciUpperLimit":"-7.43"},{"groupIds":["OG000","OG004"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean difference (Final Values)","paramValue":"-11.14","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-13.72","ciUpperLimit":"-8.56"},{"groupIds":["OG000","OG005"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean difference (Final Values)","paramValue":"-12.38","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-14.87","ciUpperLimit":"-9.90"},{"groupIds":["OG000","OG006"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean difference (Final Values)","paramValue":"-11.73","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-14.04","ciUpperLimit":"-9.43"}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Waist Circumference","description":"LS means were calculated using a MMRM model for post-baseline measures: Variable = Treatment\\*Time + Baseline BMI (\\< 36kg/m2 vs. \\>=36 kg/m2)\\*Time + Sex (Female vs. Male)\\*Time + Baseline\\*Time.","populationDescription":"All randomized participants who had baseline and at least one post-baseline waist circumference value, excluding participants discontinuing study drug due to inadvertent enrollment and data after discontinuation of study drug.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"cm","timeFrame":"Baseline, Week 48","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo matched to LY3437943 administered as SC injection QW."},{"id":"OG001","title":"1 mg LY3437943","description":"Participants received 1 mg LY3437943 administered as SC injection QW."},{"id":"OG002","title":"4 mg LY3437943 (2 mg)","description":"Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 administered as SC injection QW."},{"id":"OG003","title":"4 mg LY3437943","description":"Participants received 4 mg LY3437943 administered as SC injection QW."},{"id":"OG004","title":"8 mg LY3437943 (2 mg)","description":"Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 and then 8 mg LY3437943 administered as SC injection QW."},{"id":"OG005","title":"8 mg LY3437943 (4 mg)","description":"Participants received 4 mg LY3437943 starting dose followed by 8 mg LY3437943 administered as SC injection QW."},{"id":"OG006","title":"12 mg LY3437943 (2 mg)","description":"Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943, 8 mg LY3437943 and then 12 mg LY3437943 administered as SC injection QW."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"69"},{"groupId":"OG002","value":"32"},{"groupId":"OG003","value":"33"},{"groupId":"OG004","value":"35"},{"groupId":"OG005","value":"35"},{"groupId":"OG006","value":"62"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.64","spread":"0.99"},{"groupId":"OG001","value":"-6.49","spread":"1.12"},{"groupId":"OG002","value":"-14.58","spread":"1.56"},{"groupId":"OG003","value":"-14.87","spread":"1.73"},{"groupId":"OG004","value":"-18.53","spread":"1.46"},{"groupId":"OG005","value":"-18.50","spread":"1.52"},{"groupId":"OG006","value":"-19.60","spread":"1.29"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.010","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean difference (Final Values)","paramValue":"-3.84","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-6.77","ciUpperLimit":"-0.91"},{"groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean difference (Final Values)","paramValue":"-11.94","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-15.54","ciUpperLimit":"-8.33"},{"groupIds":["OG000","OG003"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean difference (Final Values)","paramValue":"-12.22","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-16.11","ciUpperLimit":"-8.33"},{"groupIds":["OG000","OG004"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean difference (Final Values)","paramValue":"-15.88","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-19.33","ciUpperLimit":"-12.43"},{"groupIds":["OG000","OG005"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean difference (Final Values)","paramValue":"-15.85","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-19.39","ciUpperLimit":"-12.31"},{"groupIds":["OG000","OG006"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean difference (Final Values)","paramValue":"-16.95","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-20.13","ciUpperLimit":"-13.78"}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Baseline Through End of Safety Follow-up (Up to 52 Weeks)","description":"All randomized participants who received at least one dose of study drug, regardless of adherence to study drug. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly. Frequency threshold for reporting other (not including serious) adverse event is greater than or equal to (≥) 5% in any of the treatment groups.","eventGroups":[{"id":"EG000","title":"Placebo","description":"Participants received placebo matched to LY3437943 administered as SC injection QW.","deathsNumAffected":0,"deathsNumAtRisk":70,"seriousNumAffected":3,"seriousNumAtRisk":70,"otherNumAffected":40,"otherNumAtRisk":70},{"id":"EG001","title":"1 mg LY3437943","description":"Participants received 1 mg LY3437943 administered as SC injection QW.","deathsNumAffected":0,"deathsNumAtRisk":69,"seriousNumAffected":3,"seriousNumAtRisk":69,"otherNumAffected":46,"otherNumAtRisk":69},{"id":"EG002","title":"4 mg LY3437943 (2 mg)","description":"Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 administered as SC injection QW.","deathsNumAffected":0,"deathsNumAtRisk":33,"seriousNumAffected":0,"seriousNumAtRisk":33,"otherNumAffected":22,"otherNumAtRisk":33},{"id":"EG003","title":"4 mg LY3437943","description":"Participants received 4 mg LY3437943 administered as SC injection QW.","deathsNumAffected":1,"deathsNumAtRisk":33,"seriousNumAffected":2,"seriousNumAtRisk":33,"otherNumAffected":24,"otherNumAtRisk":33},{"id":"EG004","title":"8 mg LY3437943 (2 mg)","description":"Participants received 2 mg LY343794 starting dose followed by 4 mg LY3437943 and then 8 mg LY3437943 administered as SC injection QW.","deathsNumAffected":0,"deathsNumAtRisk":35,"seriousNumAffected":1,"seriousNumAtRisk":35,"otherNumAffected":26,"otherNumAtRisk":35},{"id":"EG005","title":"8 mg LY3437943 (4 mg)","description":"Participants received 4 mg LY3437943 starting dose followed by 8 mg LY3437943 administered as SC injection QW.","deathsNumAffected":0,"deathsNumAtRisk":35,"seriousNumAffected":2,"seriousNumAtRisk":35,"otherNumAffected":31,"otherNumAtRisk":35},{"id":"EG006","title":"12 mg LY3437943 (2 mg)","description":"Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943, 8 mg LY3437943 and then 12 mg LY3437943 administered as SC injection QW.","deathsNumAffected":0,"deathsNumAtRisk":62,"seriousNumAffected":2,"seriousNumAtRisk":62,"otherNumAffected":52,"otherNumAtRisk":62}],"seriousEvents":[{"term":"Cardiac failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":69},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":33},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":33},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":35},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":62}]},{"term":"Coronary artery stenosis","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":70},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":69},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":33},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":33},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":62}]},{"term":"Pancreatitis acute","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":69},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":33},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":33},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":62}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":69},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":33},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":33},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":35},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":62}]},{"term":"Chest discomfort","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":69},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":33},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":33},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":62}]},{"term":"Drowning","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":69},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":33},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":33},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":62}]},{"term":"Cholecystitis acute","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":69},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":33},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":33},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":35},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":62}]},{"term":"Covid-19","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":69},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":33},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":33},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":35},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":62}]},{"term":"Bone contusion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":70},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":69},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":33},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":33},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":62}]},{"term":"Blood calcitonin increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":70},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":69},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":33},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":33},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":62}]},{"term":"Electrocardiogram qt prolonged","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":69},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":33},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":33},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":62}]},{"term":"Clear cell renal cell carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":69},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":33},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":33},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":62}]},{"term":"Cerebrovascular accident","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":69},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":33},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":33},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":62}]},{"term":"Acute kidney injury","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":69},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":33},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":33},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":35},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":62}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":69},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":33},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":33},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG006","numEvents":2,"numAffected":2,"numAtRisk":62}]},{"term":"Abdominal distension","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":69},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":33},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":33},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG005","numEvents":3,"numAffected":2,"numAtRisk":35},{"groupId":"EG006","numEvents":6,"numAffected":5,"numAtRisk":62}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":70},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":69},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":33},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":33},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":35},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":35},{"groupId":"EG006","numEvents":2,"numAffected":2,"numAtRisk":62}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":70},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":69},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":33},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":33},{"groupId":"EG004","numEvents":4,"numAffected":3,"numAtRisk":35},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":35},{"groupId":"EG006","numEvents":3,"numAffected":3,"numAtRisk":62}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":70},{"groupId":"EG001","numEvents":7,"numAffected":5,"numAtRisk":69},{"groupId":"EG002","numEvents":6,"numAffected":5,"numAtRisk":33},{"groupId":"EG003","numEvents":3,"numAffected":2,"numAtRisk":33},{"groupId":"EG004","numEvents":5,"numAffected":4,"numAtRisk":35},{"groupId":"EG005","numEvents":4,"numAffected":4,"numAtRisk":35},{"groupId":"EG006","numEvents":13,"numAffected":10,"numAtRisk":62}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":8,"numAtRisk":70},{"groupId":"EG001","numEvents":8,"numAffected":6,"numAtRisk":69},{"groupId":"EG002","numEvents":5,"numAffected":4,"numAtRisk":33},{"groupId":"EG003","numEvents":5,"numAffected":4,"numAtRisk":33},{"groupId":"EG004","numEvents":11,"numAffected":7,"numAtRisk":35},{"groupId":"EG005","numEvents":9,"numAffected":7,"numAtRisk":35},{"groupId":"EG006","numEvents":17,"numAffected":9,"numAtRisk":62}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":70},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":69},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":33},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":33},{"groupId":"EG004","numEvents":3,"numAffected":2,"numAtRisk":35},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":35},{"groupId":"EG006","numEvents":7,"numAffected":5,"numAtRisk":62}]},{"term":"Faeces hard","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":69},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":33},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":33},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":35},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":62}]},{"term":"Gastrooesophageal reflux disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":70},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":69},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":33},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":33},{"groupId":"EG004","numEvents":3,"numAffected":3,"numAtRisk":35},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG006","numEvents":8,"numAffected":4,"numAtRisk":62}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":8,"numAtRisk":70},{"groupId":"EG001","numEvents":12,"numAffected":10,"numAtRisk":69},{"groupId":"EG002","numEvents":9,"numAffected":6,"numAtRisk":33},{"groupId":"EG003","numEvents":21,"numAffected":12,"numAtRisk":33},{"groupId":"EG004","numEvents":9,"numAffected":6,"numAtRisk":35},{"groupId":"EG005","numEvents":33,"numAffected":21,"numAtRisk":35},{"groupId":"EG006","numEvents":63,"numAffected":28,"numAtRisk":62}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":70},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":69},{"groupId":"EG002","numEvents":6,"numAffected":4,"numAtRisk":33},{"groupId":"EG003","numEvents":5,"numAffected":4,"numAtRisk":33},{"groupId":"EG004","numEvents":3,"numAffected":2,"numAtRisk":35},{"groupId":"EG005","numEvents":9,"numAffected":9,"numAtRisk":35},{"groupId":"EG006","numEvents":21,"numAffected":12,"numAtRisk":62}]},{"term":"Early satiety","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":70},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":69},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":33},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":33},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":35},{"groupId":"EG006","numEvents":6,"numAffected":6,"numAtRisk":62}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":70},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":69},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":33},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":33},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":35},{"groupId":"EG005","numEvents":3,"numAffected":3,"numAtRisk":35},{"groupId":"EG006","numEvents":6,"numAffected":6,"numAtRisk":62}]},{"term":"Covid-19","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":14,"numAtRisk":70},{"groupId":"EG001","numEvents":13,"numAffected":13,"numAtRisk":69},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":33},{"groupId":"EG003","numEvents":6,"numAffected":6,"numAtRisk":33},{"groupId":"EG004","numEvents":6,"numAffected":6,"numAtRisk":35},{"groupId":"EG005","numEvents":11,"numAffected":11,"numAtRisk":35},{"groupId":"EG006","numEvents":15,"numAffected":15,"numAtRisk":62}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":70},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":69},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":33},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":33},{"groupId":"EG004","numEvents":4,"numAffected":3,"numAtRisk":35},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":35},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":62}]},{"term":"Sinusitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":70},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":69},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":33},{"groupId":"EG003","numEvents":3,"numAffected":1,"numAtRisk":33},{"groupId":"EG004","numEvents":2,"numAffected":1,"numAtRisk":35},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":35},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":62}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":70},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":69},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":33},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":33},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":35},{"groupId":"EG006","numEvents":2,"numAffected":2,"numAtRisk":62}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":70},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":69},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":33},{"groupId":"EG003","numEvents":2,"numAffected":1,"numAtRisk":33},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG005","numEvents":3,"numAffected":2,"numAtRisk":35},{"groupId":"EG006","numEvents":3,"numAffected":2,"numAtRisk":62}]},{"term":"Vaginal infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":33},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":30}]},{"term":"Amylase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":70},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":69},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":33},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":33},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":35},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG006","numEvents":2,"numAffected":2,"numAtRisk":62}]},{"term":"Blood creatine phosphokinase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":70},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":69},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":33},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":33},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":35},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":35},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":62}]},{"term":"Lipase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":70},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":69},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":33},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":33},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":35},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":35},{"groupId":"EG006","numEvents":5,"numAffected":5,"numAtRisk":62}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":69},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":33},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":33},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":35},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":35},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":62}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":70},{"groupId":"EG001","numEvents":10,"numAffected":9,"numAtRisk":69},{"groupId":"EG002","numEvents":6,"numAffected":6,"numAtRisk":33},{"groupId":"EG003","numEvents":8,"numAffected":8,"numAtRisk":33},{"groupId":"EG004","numEvents":5,"numAffected":4,"numAtRisk":35},{"groupId":"EG005","numEvents":12,"numAffected":11,"numAtRisk":35},{"groupId":"EG006","numEvents":19,"numAffected":18,"numAtRisk":62}]},{"term":"Allodynia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":69},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":33},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":33},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG006","numEvents":4,"numAffected":4,"numAtRisk":62}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":70},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":69},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":33},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":33},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG005","numEvents":3,"numAffected":3,"numAtRisk":35},{"groupId":"EG006","numEvents":9,"numAffected":5,"numAtRisk":62}]},{"term":"Dizziness postural","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":69},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":33},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":33},{"groupId":"EG004","numEvents":3,"numAffected":2,"numAtRisk":35},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG006","numEvents":2,"numAffected":2,"numAtRisk":62}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":69},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":33},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":33},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG005","numEvents":4,"numAffected":4,"numAtRisk":35},{"groupId":"EG006","numEvents":6,"numAffected":4,"numAtRisk":62}]},{"term":"Hyperaesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":70},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":69},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":33},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":33},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":35},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":35},{"groupId":"EG006","numEvents":2,"numAffected":2,"numAtRisk":62}]},{"term":"Erectile dysfunction","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":36},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":32}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":69},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":33},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":33},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":35},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":62}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":69},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":33},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":33},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":35},{"groupId":"EG005","numEvents":2,"numAffected":1,"numAtRisk":35},{"groupId":"EG006","numEvents":2,"numAffected":2,"numAtRisk":62}]},{"term":"Sensitive skin","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":69},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":33},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":33},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":35},{"groupId":"EG006","numEvents":2,"numAffected":2,"numAtRisk":62}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":70},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":69},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":33},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":33},{"groupId":"EG004","numEvents":3,"numAffected":3,"numAtRisk":35},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG006","numEvents":4,"numAffected":4,"numAtRisk":62}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":70},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":69},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":33},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":33},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":35},{"groupId":"EG005","numEvents":3,"numAffected":3,"numAtRisk":35},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":62}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"GT60","restrictiveAgreement":true},"pointOfContact":{"title":"Chief Medical Officer","organization":"Eli Lilly and Company","email":"ClinicalTrials.gov@lilly.com","phone":"800-545-5979"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2022-08-29","uploadDate":"2023-05-17T04:06","filename":"Prot_000.pdf","size":6359865},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2022-12-15","uploadDate":"2023-05-17T04:07","filename":"SAP_001.pdf","size":1463763}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-10-09"},"conditionBrowseModule":{"meshes":[{"id":"D009765","term":"Obesity"},{"id":"D050177","term":"Overweight"},{"id":"D008659","term":"Metabolic Diseases"},{"id":"D015431","term":"Weight Loss"},{"id":"D044343","term":"Overnutrition"}],"ancestors":[{"id":"D009748","term":"Nutrition Disorders"},{"id":"D009750","term":"Nutritional and Metabolic Diseases"},{"id":"D001835","term":"Body Weight"},{"id":"D012816","term":"Signs and Symptoms"},{"id":"D013568","term":"Pathological Conditions, Signs and Symptoms"},{"id":"D001836","term":"Body Weight Changes"}]},"interventionBrowseModule":{"meshes":[{"id":"C000729679","term":"retatrutide"}]}},"hasResults":true}